Etanercept and Stroke Recovery: Breakthrough Griffith Trial Results You Need to Hear

Etanercept and Stroke Recovery: Breakthrough Griffith Trial Results You Need to Hear

How do people cope with the challenges of staying hopeful years after a stroke? This Recovery After Stroke instalment answers that head-on by breaking down a clinical trial that suggests change might still be possible long after hospital discharge. A solo host talks directly to stroke survivors and carers, building on earlier excitement about a UCLA study in mice, then turning to a very real human trial from Griffith University in Australia.

The focus here is clear: a long‑used arthritis drug called etanercept and whether it can ease chronic post‑stroke pain, even 6 to 15 years after the original stroke. You’ll hear a plain‑English walk‑through of the trial design: 26 participants aged 30 to 80, all living with moderate to severe daily pain and one‑sided weakness. Half received perispinal etanercept injections, half got placebo.

The host explains what was measured – pain scores, shoulder movement, sensation, cognition and fatigue – and reminds you that the trial was aimed at pain first and foremost. The headline results are hard to ignore. About 70% of those on etanercept had meaningful pain relief, with an average drop of 24 points on a 0–100 scale, and some experiencing near‑complete relief within an hour.

Nine out of ten in the treatment group improved shoulder movement, and many reported better feeling of heat, cold and pressure. Side effects were limited, with one case of shingles. As the host puts it, this hints that “the brain may still be capable of healing years after a stroke” and challenges the idea that survivors have “hit a plateau.” This episode suits stroke survivors, families and health professionals who want straight talk, numbers, and realistic hope rather than hype.

It might leave you asking: if the brain can change this far out, what else could be possible for recovery?